Abbvie Inc
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio.
Generated $14.7 in free cash flow for every $1 of capital expenditure in FY25.
Current Price
$208.84
-2.86%GoodMoat Value
$131.68
36.9% overvaluedAbbvie Inc (ABBV) Reverse DCF
Abbvie Inc — Reverse DCF
ABBV · NYSE · Healthcare
GoodMoat Target
“When you're paying 86 times earnings for a company, you better be darn sure those future cash flows are as predictable as Nebraska corn harvests.”
— In the voice of Buffett
What is the Reverse DCF?
Determine what growth rate the market is pricing in. Compare implied growth against historical performance to identify mispricing.
Key Metrics
Market Cap
$369.10B
P/E Ratio
87.34
Forward P/E
—
EPS
$2.36
PEG Ratio
-0.01
Book Value
$-1.85
Dividend Yield
3.16%
Profit Margin
6.91%
ROE
—
Reverse DCF Analysis
Implied Growth
8.9%
Market expects reasonable growth aligned with historical averages.
VS BENCHMARKS
At 10% conservative growth:
Fair Value
$222.38
MOS
+6%
Buy Below
$166.78
Adjust Parameters
Abbvie Inc (ABBV) Reverse DCF
Determine what growth rate the market is pricing in. Compare implied growth against historical performance to identify mispricing.
Abbvie Inc is a Healthcare company in the Drug Manufacturers - General industry, listed on NYSE. Current stock price: $208.84. Market capitalization: $369.10B. EPS: $2.36. P/E ratio: 87.34.
GoodMoat Fair Value target: $131.68. The stock appears 58.6% overvalued based on our blended model.
Use GoodMoat's Reverse DCF alongside other valuation tools including DCF Calculator, Reverse DCF, Fair Value models, and Quality Score to build a comprehensive investment thesis for Abbvie Inc (ABBV). All tools are free to use and powered by real-time financial data.